Start-Up Archer Preps Alzheimer’s Drugs For Phase I
This article was originally published in The Pink Sheet Daily
Executive Summary
IND filed, company aims to use nilvadipine derivative against soluble amyloid.
You may also be interested in...
The Alzheimer’s Divide: Wyeth Phase II Underscores Key Choice For Sponsors
Wyeth/Elan's Phase II bapineuzumab trial for Alzheimer's disease did not impress investors, but the sponsors are convinced they made the right bet in how they designed the study
Industry Roundtable: Neurotech Execs Discuss Innovation, Challenges, Next Steps
In Part I of a series, panelists discuss outcomes measures in a sector with unique regulatory conditions and the need for biomarkers.
Lilly Makes Big Biologics Play For Alzheimer’s
But study published in Lancet raises questions about efficacy of anti-amyloid therapy.